Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
Karuna Therapeutics, Inc. announced financial results for the first quarter of 2023 and provided a general business update.
Uncategorized
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reported financial results and provided business updates for the first quarter of 2023.
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates Read More »
El cibermareo provocado por el uso de realidad virtual
Poco a poco, la realidad virtual va abriéndose paso en campos como el de los videojuegos y el educativo. Sin embargo, el uso de realidad virtual puede tener efectos secundarios. De entre ellos, el más común es un mareo que, por su origen, se ha dado en llamar “cibermareo&r …
El cibermareo provocado por el uso de realidad virtual Read More »
Detectan un planeta devorado por su estrella
Un nuevo estudio documenta la primera observación clara de una estrella envejecida que se traga un planeta. Tras quedarse sin combustible en su núcleo, la estrella comenzó a crecer en tamaño, reduciendo la distancia con su planeta vecino, para finalmente engullirlo. Dentr …
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of Alvotech’s confirmatory patient study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.
XNK Therapeutics Enters into Research Agreement with Global Pharma Company
XNK Therapeutics AB announced that the company’s autologous natural killer cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.
XNK Therapeutics Enters into Research Agreement with Global Pharma Company Read More »
AlzeCure Publishes its Interim Report for January – March 2023
AlzeCure Pharma AB announced that its interim report for the period January – March 2023 is now available on the company’s website.
AlzeCure Publishes its Interim Report for January – March 2023 Read More »
Hasten Biopharma Acquires Commercial Rights in China for Roche’s Antibiotic Rocephin®
Hasten Biopharmaceutic Co., Ltd announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.
Hasten Biopharma Acquires Commercial Rights in China for Roche’s Antibiotic Rocephin® Read More »
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
PureTech Health plc, a clinical-stage biotherapeutics company noted that its Founded Entity, Akili, Inc., a leading digital medicine company, announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRxⓇ in adults with attention-deficit/hyperactivity disorder.
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering
Mekonos, Inc. has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering Read More »